Amylyx Pharmaceuticals (AMLX) Operating Expenses (2021 - 2026)

Amylyx Pharmaceuticals has reported Operating Expenses for 6 years, with the latest figure at $45.7 million in Q2 2026.

• On a quarterly basis, Operating Expenses rose 6.62% year-over-year to $45.7 million in Q2 2026; TTM through Jun 2026 was $162.1 million, a 17.6% decrease from a year earlier, with the FY2025 full-year figure at $153.3 million, down 61.88% from the prior year.
• Operating Expenses was $45.7 million for Q2 2026 at Amylyx Pharmaceuticals, up from $43.8 million in the prior quarter.
• The five-year high for Operating Expenses was $210.8 million in Q1 2024, with the low at $36.0 million in Q3 2025.
• Average Operating Expenses over 5 years is $67.2 million, with a median of $54.6 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses surged 271.57% in 2022, then plunged 82.06% in 2025.
• Over 5 years, Operating Expenses stood at $66.5 million in 2022, then surged by 60.23% to $106.5 million in 2023, then sank by 62.46% to $40.0 million in 2024, then slipped by 8.46% to $36.6 million in 2025, then grew by 24.83% to $45.7 million in 2026.
• The last three Operating Expenses figures came in at $45.7 million (Q2 2026), $43.8 million (Q1 2026), and $36.6 million (Q4 2025), per Business Quant data.